ATE311201T1 - Testosteron-ester formulierung zur anwendung am menschen - Google Patents

Testosteron-ester formulierung zur anwendung am menschen

Info

Publication number: ATE311201T1
Authority: AT; Austria
Prior art keywords: testosterone; human use; testosterone ester; ester formulation; formulation
Prior art date: 2000-08-23

Application number

AT01971928T

Other languages

English (en)

Inventor

Nijs Henrik De

Wendy Margaretha Kersemaekers

Sephanus Cornelis Schutte

Bruggen Johann Gerhard Cor Van

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-23

Filing date

2001-08-17

Publication date

2005-12-15

2001-08-17 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE311201T1 publication Critical patent/ATE311201T1/de

Links

MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 5
238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
229960003604 testosterone Drugs 0.000 title abstract 3
-1 TESTOSTERONE ESTER Chemical class 0.000 title 1
ORGPUALGNXTPAW-UHFFFAOYSA-N 2,6-dichloro-n-(1-cyanocycloheptyl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1(C#N)CCCCCC1 ORGPUALGNXTPAW-UHFFFAOYSA-N 0.000 abstract 4
229960003410 testosterone decanoate Drugs 0.000 abstract 4
150000002148 esters Chemical class 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)

AT01971928T 2000-08-23 2001-08-17 Testosteron-ester formulierung zur anwendung am menschen ATE311201T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00202939		2000-08-23
PCT/EP2001/009569 WO2002015938A2 (en)	2000-08-23	2001-08-17	Testosterone ester formulation for human use

Publications (1)

Publication Number	Publication Date
ATE311201T1 true ATE311201T1 (de)	2005-12-15

Family

ID=8171940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01971928T ATE311201T1 (de)	2000-08-23	2001-08-17	Testosteron-ester formulierung zur anwendung am menschen

Country Status (15)

Country	Link
US (1)	US20050101517A1 (de)
EP (1)	EP1313511B1 (de)
JP (1)	JP2004506698A (de)
CN (1)	CN1248738C (de)
AT (1)	ATE311201T1 (de)
AU (2)	AU2001291775B2 (de)
BR (1)	BR0113376A (de)
CA (1)	CA2415349A1 (de)
CY (1)	CY1106064T1 (de)
DE (1)	DE60115464T2 (de)
DK (1)	DK1313511T3 (de)
ES (1)	ES2253423T3 (de)
IL (2)	IL153648A0 (de)
MX (1)	MXPA03001147A (de)
WO (1)	WO2002015938A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200404552A (en) *	2002-05-30	2004-04-01	Akzo Nobel Nv	Self administered contraception
JO2505B1 (en)	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
IL157535A0 (en) *	2003-08-21	2004-03-28	Topimed Ltd	Preparations for the prevention of skin atrophy
US8541413B2 (en) *	2004-10-01	2013-09-24	Ramscor, Inc.	Sustained release eye drop formulations
MX2007003968A (es) *	2004-10-01	2008-03-04	Ramscor Inc	Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US9993558B2 (en)	2004-10-01	2018-06-12	Ramscor, Inc.	Sustained release eye drop formulations
US20080038316A1 (en) *	2004-10-01	2008-02-14	Wong Vernon G	Conveniently implantable sustained release drug compositions
US8241664B2 (en)	2005-04-15	2012-08-14	Clarus Therapeutics, Inc	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20110160168A1 (en)	2009-12-31	2011-06-30	Differential Drug Development Associates, Llc	Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
WO2014143127A1 (en)	2013-03-15	2014-09-18	Differential Drug Development Associates Llc	Emulsion formulations
TW201521731A (zh) *	2013-03-15	2015-06-16	利波辛股份有限公司	用於口服之脂平衡的長鏈睪固酮酯
US10245273B2 (en)	2013-12-26	2019-04-02	Clarus Therapeutics, Inc.	Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
WO2018064556A1 (en)	2016-09-29	2018-04-05	Gesea Biosciences Inc.	Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
EP3824296B1 (de)	2018-07-20	2026-04-01	Lipocine Inc.	Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
US11564933B2 (en)	2019-04-12	2023-01-31	Tolmar, Inc.	Methods of treating testosterone deficiency
US12403146B2 (en)	2019-10-30	2025-09-02	Marius Pharmaceuticals, Inc.	Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB465331A (en) *	1935-10-05	1937-05-05	Chem Ind Basel	Manufacture of new esters of polynuclear cyclic oxyketones
US4098802A (en) *	1975-02-18	1978-07-04	Akzona Incorporated	Oral pharmaceutical preparation having androgenic activity
US4147783A (en) *	1974-02-28	1979-04-03	Akzona Incorporated	Oral pharmaceutical preparation
NL189235C (nl) *	1974-02-28	1993-02-16	Akzo Nv	Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
NL7506407A (nl) *	1975-05-30	1976-12-02	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
GB1567515A (en) *	1976-05-28	1980-05-14	Akzo Nv	Esters of testo-sterone and 5 -dihydro-testosterone
DE19975054I2 (de) *	1987-08-08	2000-04-13	Akzo Nobel Nv	Kontrazeptives Implantat
US6063395A (en) *	1998-11-12	2000-05-16	Leiras Oy	Drug delivery device especially for the delivery of progestins and estrogens
US7025979B2 (en) *	2000-02-15	2006-04-11	Schering Ag	Male contraceptive formulation comprising norethisterone

2001
- 2001-08-17 MX MXPA03001147A patent/MXPA03001147A/es active IP Right Grant
- 2001-08-17 BR BR0113376-4A patent/BR0113376A/pt not_active IP Right Cessation
- 2001-08-17 EP EP01971928A patent/EP1313511B1/de not_active Expired - Lifetime
- 2001-08-17 CA CA002415349A patent/CA2415349A1/en not_active Abandoned
- 2001-08-17 US US10/362,350 patent/US20050101517A1/en not_active Abandoned
- 2001-08-17 DE DE60115464T patent/DE60115464T2/de not_active Expired - Fee Related
- 2001-08-17 DK DK01971928T patent/DK1313511T3/da active
- 2001-08-17 ES ES01971928T patent/ES2253423T3/es not_active Expired - Lifetime
- 2001-08-17 AU AU2001291775A patent/AU2001291775B2/en not_active Ceased
- 2001-08-17 CN CNB018130542A patent/CN1248738C/zh not_active Expired - Fee Related
- 2001-08-17 IL IL15364801A patent/IL153648A0/xx active IP Right Grant
- 2001-08-17 AT AT01971928T patent/ATE311201T1/de not_active IP Right Cessation
- 2001-08-17 JP JP2002520859A patent/JP2004506698A/ja active Pending
- 2001-08-17 AU AU9177501A patent/AU9177501A/xx active Pending
- 2001-08-17 WO PCT/EP2001/009569 patent/WO2002015938A2/en not_active Ceased
2002
- 2002-12-25 IL IL153648A patent/IL153648A/en not_active IP Right Cessation
2006
- 2006-01-27 CY CY20061100113T patent/CY1106064T1/el unknown

Also Published As

Publication number	Publication date
EP1313511A2 (de)	2003-05-28
DK1313511T3 (da)	2006-03-20
AU2001291775B2 (en)	2005-09-08
AU9177501A (en)	2002-03-04
CN1443078A (zh)	2003-09-17
DE60115464D1 (de)	2006-01-05
CN1248738C (zh)	2006-04-05
IL153648A (en)	2009-02-11
US20050101517A1 (en)	2005-05-12
DE60115464T2 (de)	2006-06-14
MXPA03001147A (es)	2003-10-06
BR0113376A (pt)	2003-07-15
EP1313511B1 (de)	2005-11-30
JP2004506698A (ja)	2004-03-04
IL153648A0 (en)	2003-07-06
WO2002015938A2 (en)	2002-02-28
WO2002015938A8 (en)	2004-03-04
ES2253423T3 (es)	2006-06-01
CY1106064T1 (el)	2011-06-08
CA2415349A1 (en)	2002-02-28
WO2002015938A3 (en)	2002-08-15

Legal Events

Date

Code

Title

Description

2006-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1313511

Country of ref document: EP

2010-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60115464D1 (de)	2006-01-05	Testosteron-ester formulierung zur anwendung am menschen
ATE367087T1 (de)	2007-08-15	Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
PA8481501A1 (es)	2001-12-14	4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
AU2001249360A1 (en)	2001-10-08	Low fat nut spread composition with high protein and fiber
TW200631597A (en)	2006-09-16	External use preparation and adhesive preparation thereof
BR0115323A (pt)	2004-02-17	Uso de cci-779 como agente antineoplástico
IL181234A0 (en)	2007-07-04	Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
CA2216887A1 (en)	1999-03-30	Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
NZ522242A (en)	2004-12-24	Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
NO20023102L (no)	2002-08-30	Fremgangsmåte og formulering for behandling av residens mot anti-hypertensiver og relaterte tilstander
BR0210101A (pt)	2004-06-08	Combinações antineoplásticas
IL138290A0 (en)	2001-10-31	Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE59906362D1 (de)	2003-08-28	Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
WO2004052294A3 (en)	2004-08-26	Compositions and methods related to lipid:emodin formulations
AU2001265186A1 (en)	2001-12-11	Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
NL1010351A1 (nl)	2000-04-28	Esters van carotenoïden voor gebruik in de preventie en behandeling van oogaandoeningen.
DE60331963D1 (de)	2010-05-12	Stabile pharmazeutische zubereitungen zur kontrollierten freisetzung von fenofibrat and pravastatin
TR199800597T1 (xx)	1998-06-22	Papillum ait deri iltihab� tedavisi ve �nlenmesi.
DE59911381D1 (de)	2005-02-03	Verwendung von testosteronestern und/oder testosteron zur herstellung von bukkal applizierbaren bioadhasiven systemen mit zeitgesteuerter arzneistoffwirkung
PT1313500E (pt)	2005-02-28	Associacoes de dalfopristina/quinupristina com o cefpirome
NO20031080L (no)	2003-05-21	Fettsyreanaloger for behandling av proliferative sykdommer
UA29506C2 (uk)	2000-11-15	Лікувально-косметичний засіб "фіто-пелоїд"
WO2000051577A3 (en)	2001-01-25	Use of fluorinated triazoles for treating pain and affective or attention disorders
WO1999016429A3 (en)	2001-12-20	Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
NZ504525A (en)	2003-01-31	Use of cetyl alcohol esters of myristic and palmitic acids to treat eczema and psoriasis